Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Aprilbio Co., Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, meaning that each active case is being reviewed by a different individual. This variety requires the applicant to manage two separate prosecution tracks simultaneously.
The prosecution activity is concentrated within 1 distinct art unit, suggesting that despite the involvement of 2 distinct examiners, the technical subject matter remains within a single specialized group at the USPTO. SZPERKA, MICHAEL EDWARD is the busiest examiner for the company, currently overseeing 1 pending office action. This indicates an even distribution of the workload between the two examiners.
For a practitioner, this data reflects a portfolio where 1 distinct art unit is the primary regulatory environment for all active matters. Since the 2 pending office actions are split between 2 distinct examiners, the applicant must address the specific preferences of both SZPERKA, MICHAEL EDWARD and the other examiner. This requires a strategy that is consistent with the standards of the single art unit while being tailored to the individual feedback of each examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246423 | Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof | SZPERKA, MICHAEL EDWARD | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246423 | Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof | SZPERKA, MICHAEL EDWARD | 5d overdue |
| 17759313 | MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246423 | Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof | SZPERKA, MICHAEL EDWARD | 1641 | §101§103Other | Final Rejection | 5d overdue | Pending | Mar 23, 2023 |
| 17759313 | MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF | ROONEY, NORA MAUREEN | 1641 | §112 | Non-Final OA | — | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAprilbio Co., Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Michael Edward Szperka has the most, with 1 of Aprilbio Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
